Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | GCK | P35557 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18941216 | 0.93 | KMT2A (0.60) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941186 | 0.91 | MAPT (0.72) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941063 | 0.89 | KMT2A (0.64) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941145 | 0.89 | RAB9A (0.66) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941127 | 0.85 | KMT2A (0.78) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941068 | 0.82 | KMT2A (0.66) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941339 | 0.82 | CASP3 (0.55) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941086 | 0.82 | KMT2A (0.59) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941288 | 0.81 | MAPT (0.77) | KMT2AMAPTMEN1RAB9ATP53 | |
| SCHEMBL18941237 | 0.81 | KMT2A (0.66) | KMT2AMAPTMEN1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | KMT2A 2215/4885MAPT 2167/4885MEN1 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.